Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development.

Junker LM, Clardy J.

Antimicrob Agents Chemother. 2007 Oct;51(10):3582-90. Epub 2007 Jul 30.

2.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2015 Mar 5;(3):CD009528. doi: 10.1002/14651858.CD009528.pub3. Review.

PMID:
25741986
3.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;3:CD009528.

PMID:
23152277
4.

Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.

Jakobsen TH, Bjarnsholt T, Jensen PØ, Givskov M, Høiby N.

Future Microbiol. 2013 Jul;8(7):901-21. doi: 10.2217/fmb.13.57. Review.

PMID:
23841636
5.

Next generation biofilm inhibitors for Pseudomonas aeruginosa: Synthesis and rational design approaches.

Majik MS, Parvatkar PT.

Curr Top Med Chem. 2014;14(1):81-109. Review.

PMID:
24236724
6.

Pseudomonas aeruginosa biofilm: potential therapeutic targets.

Sharma G, Rao S, Bansal A, Dang S, Gupta S, Gabrani R.

Biologicals. 2014 Jan;42(1):1-7. doi: 10.1016/j.biologicals.2013.11.001. Epub 2013 Dec 3. Review.

PMID:
24309094
7.
8.

Molecular Mechanisms of Biofilm Infection: Biofilm Virulence Factors.

Phillips PL, Schultz GS.

Adv Wound Care (New Rochelle). 2012 Jun;1(3):109-114. Review.

Supplemental Content

Support Center